Search Results
Your search for ,twO matches 12333 pages
Showing 5451 - 5500Update to FDA Prescribing Information for Romiplostim for Adults With Immune Thrombocytopenia
On October 18, the U.S. Food and Drug Administration (FDA) approved a supplemental biologics license application (sBLA) for romiplostim (Nplate) to include new data in its U.S. prescribing information showing sustained platelet responses in adults with immune thrombocytopenia. The updated...
Landmark Studies Show Clear Overall Survival Benefit for CDK4/6 Inhibitors in Advanced Breast Cancer
CDK4/6 inhibitors clearly improve overall survival in advanced breast cancer, as this prized endpoint was robustly demonstrated in two landmark phase III trials reported at the European Society for Medical Oncology (ESMO) Congress 2019. Dennis J. Slamon, MD, PhD, of the University of California,...
The Future of the Radiation Abscopal Response
“Two roads diverged in a wood, and I—I took the one less traveled by,And that has made all the difference.” –Robert Frost One of the first patients I encountered after residency was a 26-year-old woman with a single brain metastasis from melanoma. For anonymity, let’s call her Anna. Anna had just...
Cancer Researcher Mary J.C. Hendrix, PhD, Returns to West Virginia to Lead Her Alma Mater
Nationally regarded melanoma researcher Mary J.C. Hendrix, PhD, was born in La Jolla, California, a seaside community surrounded by ocean bluffs and beaches within the city of San Diego. She was reared in a Navy family that moved from the West Coast to the East Coast during her childhood,...
Role of Radiotherapy for Patients With Refractory Lymphoma Receiving CAR T-Cell Therapy
Although the role of radiotherapy in chimeric antigen receptor (CAR) T-cell therapy for lymphoma is still evolving, radiotherapy “would be an ideal bridging therapy” for patients with chemorefractory diffuse large B-cell lymphoma, stated George Mikhaeel, MD, Professor of Radiation Oncology and...
Three Phase III Trials Suggest Paradigm Shift With PARP Inhibitors in Ovarian Cancer
Ovarian cancer is typically a second-tier newsmaker at the world’s premier oncology conferences, but at the European Society for Medical Oncology (ESMO) Congress 2019, this tumor type generated universal buzz. Impressive findings were presented for three PARP inhibitors in front-line maintenance...
Phase III Evidence Supports Neoadjuvant Immunotherapy Plus Chemotherapy for Early Triple-Negative Breast Cancer
Immunotherapy has changed the treatment paradigms for melanoma, lung cancer, bladder cancer, and renal cancer. Now, checkpoint inhibitor therapy is making inroads in triple-negative breast cancer—one of the most difficult-to-treat aggressive types of breast cancer. The addition of the checkpoint...
Pegilodecakin Plus Pembrolizumab or Nivolumab in Advanced Solid Tumors
In a phase Ib trial reported in The Lancet Oncology, Naing et al found that the combination of pegilodecakin (pegylated interleukin [IL]-10) with the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab or nivolumab was active in previously treated advanced solid tumors. In the study,...
FDA Pipeline: Designations for Acute Graft-vs-Host Disease, Peripheral T-Cell Lymphoma
Recently, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to a therapy for steroid-refractory acute graft-vs-host disease and granted Orphan Drug designation to a therapy for peripheral T-cell lymphoma. Fast Track Designation for T-Guard in Steroid-Refractory Acute...
Effect of Patient General Preference for More vs Less Medical Care on Intensity of Posttreatment Thyroid Cancer Surveillance
In an analysis reported in the Journal of Clinical Oncology, Evron et al found that patients with thyroid cancer who were declared disease-free after initial treatment were more likely to have increased numbers of physician visits and imaging tests if they reported a generalized preference for...
FLAURA Trial: First-Line Osimertinib Improves Overall Survival in EGFR-Mutated Advanced Lung Cancer
First-line treatment with osimertinib extended overall survival compared with the older tyrosine kinase inhibitors gefitinib and erlotinib in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), according to late-breaking final overall survival results of the phase III FLAURA...
Anti-GD2 Monoclonal Antibody Plus Induction Chemotherapy in High-Risk Neuroblastoma
A phase II study evaluating whether combining an investigational anti-GD2 monoclonal antibody with induction chemotherapy improved outcomes in children with newly diagnosed high-risk neuroblastoma found that the therapy significantly improved 2-year event-free survival. Furman et al published the...
Nivolumab vs Chemotherapy in Previously Treated Advanced Esophageal Squamous Cell Carcinoma
As reported in The Lancet Oncology by Kato et al, the phase III ATTRACTION-3 trial conducted in predominantly Asian patients has shown a survival benefit with nivolumab vs paclitaxel or docetaxel in patients with advanced esophageal squamous cell carcinoma who were refractory to or intolerant of...
High Blood Pressure and Cardiac Adverse Events in Patients Treated With Ibrutinib
Over half of patients treated with the Bruton’s tyrosine kinase inhibitor ibrutinib developed new or worsened high blood pressure within 6 months of starting the medication, according to a study published by Dickerson et al in Blood. The analysis is also the first to tie ibrutinib-related...
Studies Suggest Early Salvage Radiotherapy May Be Preferable to Adjuvant Radiotherapy After Prostatectomy
Early salvage radiotherapy appears to be a better choice after radical prostatectomy for men with prostate cancer than adjuvant radiotherapy, according to late-breaking results from the RADICALS-RT trial and the ARTISTIC meta-analysis of three trials that included RADICALS-RT. Observation after...
ASCO Breakthrough: Breast Cancer Gene-Expression Signature May Help Predict Recurrence Postradiotherapy
Researchers have identified a gene pattern that may help predict which patients with breast cancer will have early or late disease recurrence following radiation therapy. The ability to predict the timing of recurrence could change—and improve—treatment strategies and determine the length of...
ASCO Breakthrough: Effect of ATM Mutations on Response to Radiotherapy
Somatic mutations of DNA damage repair genes like ATM and BRCA1 or BRCA2 may result in poor disease prognosis and chemotherapy resistance. However, a study by Lee et al presented at ASCO Breakthrough: A Global Summit for Oncology Innovators (Abstract 130) investigated the possibility that these...
ASCO Breakthrough: Computer-Aided Diagnosis System for Detecting Lung Nodule Locations and Characteristics
A computer-aided diagnosis system using deep-learning analysis to detect lung lesion locations and quantitatively characterize the lesions on computed tomography (CT) images offered a fast and convenient approach for assisting radiologists in the diagnosis of lung nodule pathologies. These findings ...
Plasma miR371 Expression as a Biomarker for Active Germ Cell Malignancy
In a study reported in the Journal of Clinical Oncology, Nappi et al showed that plasma microRNA miR371 expression was associated with high specificity and positive predictive values in predicting active germ cell malignancy. Study Details The study included 111 patients with a history of or newly ...
Mindfulness Training for Men Diagnosed With Prostate Cancer Who Are on Active Surveillance
GUEST EDITOR Integrative Oncology is guest edited by Jun J. Mao, MD, MSCE, Laurance S. Rockefeller Chair in Integrative Medicine and Chief of Integrative Medicine Service at Memorial Sloan Kettering Cancer Center, New York. The ASCO Post’s Integrative Oncology series is intended to facilitate the...
Care of Malignant Bowel Obstruction in Patients With Advanced Gynecologic Cancer
In a single-center retrospective study reported in the Journal of Oncology Practice, Lee et al found that implementation of an interprofessional malignant bowel obstruction program changed care patterns and improved outcomes for women with advanced gynecologic cancers and malignant bowel...
Ariel Hollinshead Hyun, PhD, a Pioneer in Cancer Vaccines, Dies at Age 90
Inspiration comes in many forms. For cancer researcher Ariel Hollinshead Hyun, PhD, known professionally as Dr. Hollinshead, it came at the age of 15, when she was captivated by Paul de Kruif’s book Microbe Hunters. She was fascinated by the lives of early bacteriologists detailed in the book and...
A Tale of Two Eugenes
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Higher-Volume Cancer Centers and Patient Outcomes Studies
RESEARCHERS FROM Fox Chase Cancer Center have discovered a link between higher patient volume at cancer facilities and improved survival in two studies of patients with advanced cancer.1,2 These data underscore the ability of a higher-volume facility to provide patients with more experience and...
Study Shows Benefits of Comprehensive Tobacco Treatment Program
Findings from a large smoking cessation study in patients with cancer indicate comprehensive tobacco treatment is effective in helping individuals successfully quit and abstain from smoking. The prospective study, published by Paul Cinciripini, PhD, Chair of Behavioral Science at the MD Anderson...
Featured Conversations
Developed by Conquer Cancer, the Your Stories podcast series shares unscripted conversations among patients, doctors, and the family and friends who conquer cancer with them. The series also includes transcripts of conversations. In one such featured conversation, “Doctors’ Orders,” two seasoned...
New Results From the TAPUR Study Reported in JCO Precision Oncology
New results from ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study demonstrated that single-agent palbociclib has no meaningful clinical activity in patients with CDKN2A-mutated or -deleted advanced pancreatic adenocarcinoma and cholangiocarcinoma. The results, based on data...
Kidney Cancer Association Announces Recipients of Advanced Discovery and Young Investigator Awards
The Kidney Cancer Association has announced the recipients of the Advanced Discovery Awards (ADAs) and Young Investigator Awards (YIAs). In April, the Kidney Cancer Association approved $1.3 million in new grant funding to advance early detection and new treatments of kidney cancer. Established...
Engage, Discuss, and Learn With ASCO eLearning Multidisciplinary Molecular Tumor Boards
The ASCO eLearning Multidisciplinary Molecular Tumor Boards (MMTBs) offer participants an opportunity to learn from experts and from each other on a variety of tumor-based topics. MMTB formats alternate between slide-based and discussion forum-based layouts. The discussion-based MMTBs are an...
Gene Therapy: A March Forward!
GUEST EDITORS Dr. Abutalib is Associate Director, Hematology and Cellular Therapy Program and Director, Clinical Apheresis Program Cancer Treatment at Centers of America, Zion, Illinois; Associate Professor, Rosalind Franklin University of Medicine and Science; and Founder and Co-Editor of...
Multimodal Therapy for High-Risk or Locally Advanced Endometrial Cancer: Is It Any Clearer in 2019?
Endometrial cancer remains the most common gynecologic malignancy affecting women in the United States. There are over 60,000 new cases diagnosed and more than 12,000 deaths annually. Traditional management includes surgical staging, with optimal disease cytoreduction as able, and adjuvant...
Younger, Fit Patients With CLL: Goal Remains Undetectable Minimal Residual Disease and Time-Limited Therapy
As reviewed in this issue of The ASCO Post, Shanafelt and colleagues recently published the interim analysis of E1912, a U.S. Intergroup–led randomized phase III trial comparing ibrutinib/rituximab, followed by ibrutinib to disease progression vs 6 months of fludarabine, cyclophosphamide, and...
Entrectinib for NTRK-Positive Solid Tumors and ROS1-Positive Lung Cancer
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On August 15, 2019, the oral TRK, ROS1, and ALK kinase...
Reflecting on My First National Presentation
I gave my first national presentation of my original clinical research on a topic that was to become a professional obsession: finding a cure for esophageal cancer. (Spoiler, I failed.) It was late May 1982. Writing about this now is undoubtedly predicated on my recent retirement, my desire to...
Studies Report Prolonged Long-Term Survival With Immunotherapy vs Chemotherapy in Advanced NSCLC
Longer-term follow-up of patients with advanced non–small cell lung cancer (NSCLC) who are treated with immunotherapy have appreciably extended survival at 5 years, suggesting that for some patients, this disease can be managed as a chronic condition. These findings are based on two presentations ...
Inequities in Care for Patients With Cancer and Serious Mental Illness
Studies show that people suffering from serious mental illness are at increased risk for poor cancer outcomes and mortality due to inequities in their cancer care. Although psychiatric care at the time of diagnosis may improve care, current models for integrating psychiatric interventions and...
ESMO 2019: Interim Analysis of the BEACON CRC Trial
In an interim analysis of the phase III BEACON CRC trial reported at the European Society for Medical Oncology (ESMO) Congress 2019 (Abstract LBA32) and in The New England Journal of Medicine, Scott Kopetz, MD, PhD, and colleagues found improved overall survival and overall response rate in...
ESMO 2019: Overall Survival With Immunotherapy Doublet vs Chemotherapy in Advanced NSCLC
As reported at the European Society for Medical Oncology (ESMO) Congress 2019 (Abstract LBA4) and simultaneously in The New England Journal of Medicine by Matthew D. Hellmann, MD, and colleagues, the phase III CheckMate 227 trial has shown that nivolumab plus ipilimumab improved overall survival vs ...
How to Help Terminally Ill Patients Find Peace in the Dying Process
End-of-Life Oncology is a new occasional column in The ASCO Post that will explore how to ensure the care received by terminally ill patients is in alignment with their end-of-life goals and wishes. In this inaugural installment, The ASCO Post talked with Lillie D. Shockney, RN, BS, MAS,...
2019 Nobel Prize in Physiology or Medicine Announced
Today, the Nobel Assembly at Karolinska Institutet announced its decision to award the 2019 Nobel Prize in Physiology or Medicine jointly to William G. Kaelin Jr, MD; Sir Peter J. Ratcliffe, FRS; and Gregg L. Semenza, MD, PhD, for their discoveries of how cells sense and adapt to oxygen...
Pembrolizumab for Relapsed or Refractory Mycosis Fungoides and Sézary Syndrome
In a phase II study reported in the Journal of Clinical Oncology, Khodadoust et al found that pembrolizumab was active in patients with advanced relapsed or refractory mycosis fungoides or Sézary syndrome. In the U.S.-based multicenter trial, 24 patients with advanced mycosis fungoides (n = 9) or...
ESMO 2019: Veliparib Plus First-Line Chemotherapy and as Maintenance Therapy in High-Grade Serous Ovarian Cancer
In the phase III VELIA/GOG-3005 trial—reported at the European Society for Medical Oncology (ESMO) Congress 2019 (Abstract LBA3) and simultaneously published in The New England Journal of Medicine—Robert L. Coleman, MD, and colleagues found that the use of the poly (ADP-ribose) polymerase inhibitor ...
Addition of Ribociclib to Endocrine Therapy in Advanced Breast Cancer: MONALEESA-7
As reported in TheNew England Journal of Medicine by Seock‑Ah Im, MD, PhD, of Seoul National University College of Medicine, and colleagues, an interim analysis in the phase III MONALEESA-7 trial has shown an overall survival benefit with the addition of the cyclin-dependent kinase 4 and 6 (CDK4/6) ...
FDA Pipeline: Advances in Prostate Cancer, Urothelial Cancer, Myelofibrosis, and More
In the past few weeks, the U.S. Food and Drug Administration (FDA) has issued regulatory decisions in prostate cancer, urothelial cancer, myelofibrosis, breast cancer, pediatric brain cancer, leukemia, and skin cancer. Breakthrough Therapy Designation for Niraparib in Metastatic...
Selpercatinib: Precision Medicine for RET Fusion–Positive NSCLC
Selpercatinib (LOXO-292), a RET kinase inhibitor, demonstrated antitumor activity in the lungs and brain and durable responses with acceptable tolerability in patients with RET fusion–positive non–small cell lung cancer (NSCLC), according to an updated analysis of the LIBRETTO-001 registration...
News in Ovarian Cancer From ESMO 2019
This week, we review two studies from a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2019 focusing on the efficacy of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with newly diagnosed ovarian cancer.
Durvalumab Plus Chemotherapy: New Option for Extensive-Stage SCLC
The addition of the immune checkpoint inhibitor durvalumab to standard therapy significantly improved overall survival vs standard therapy alone for patients with previously untreated extensive-stage small cell lung cancer (SCLC), according to a preplanned interim analysis of the phase III CASPIAN...
ESMO 2019: Study Suggests Difference in Response to Immunotherapy Regimens Between Sexes
A meta-analysis of 16 phase III randomized clinical trials evaluating programmed cell death protein 1/ligand 1 (PD-1/-L1) inhibitors either alone or in combination with chemotherapy for solid tumors has found that women derived significantly greater benefit from the addition of chemotherapy to...
ESMO 2019: High Conversion Rate With Certain Induction Chemotherapy Regimens Is Associated With Improved Overall Survival in Locally Advanced Pancreatic Cancer
Induction chemotherapy with nab-paclitaxel plus gemcitabine or sequential FOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, and irinotecan) followed by surgical exploration induced high conversion rates in patients with locally advanced pancreatic cancer, and conversion was associated with...
Greater Consensus From Global Experts on Controversies in Prostate Cancer
In late August, experts from around the globe convened in Basel, Switzerland, at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) to discuss controversial areas related to the management of advanced prostate cancer. Although the full proceedings of the conference will be published in...
